RecruitingNot ApplicableNCT05789030

Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement

Sponsor

Peking Union Medical College Hospital

Enrollment

60 participants

Start Date

Jul 1, 2022

Study Type

INTERVENTIONAL

Conditions

Autoimmune Diseases

Summary

This study has been designed as a 12-month, open-label randomized controlled clinical trial. The study aims to compare the efficacy and safety of two treatment strategies in IgG4-RD patients with superficial organ involvement: prednisone plus iguratimod and prednisone plus leflunomide.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called glucocorticoid plus iguratimod and a drug called glucocorticoid plus leflunomide for people with autoimmune diseases. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGglucocorticoid plus iguratimod

Patients in Group I are treated with prednisone (≤20 mg qd, or equivalent glucocorticoid, taper to ≦ 5mg in 3 months) and iguratimod (25 mg bid).

DRUGglucocorticoid plus leflunomide

Patients in Group II are treated with prednisone (≤20 mg qd, or equivalent glucocorticoid, taper to ≦ 5mg in 3 months ) and leflunomide (10-20 mg qd).